Literature DB >> 26589512

Prognostic Factors for Breast Cancer: an Immunomorphological Update.

Luca Roncati1,2, Giuseppe Barbolini3, Federico Piacentini4, Francesco Piscioli5, Teresa Pusiol5, Antonio Maiorana3.   

Abstract

The prognostic variability recorded within homogeneous groups of patients for anatomo-clinical disease stages has led to a more detailed biological characterization of breast cancer. Recently, the attention of the scientific community has focused on the role of tumor-infiltrating lymphocytes (TILs). Therefore, the need of an in-depth immunomorphological characterization of TILs has been emerged. The presence of TILs has been retrospectively investigated in 113 female cases of ductal carcinoma. An immunohistochemical investigation with CD3, CD4, CD8, CD20, CD56, granulysin, perforin-1, granzyme-B and TIA-1 was performed according to the standard procedures on all 17 cases with TILs evidence. TILs consisted of T and B lymphocytes: the prevalent population showed a T immunoprofile with a CD8-immunopositive killer subpopulation (Tk), close-linked to carcinomatous cells, and a CD4-immunopositive helper subpopulation (Th), inside the tumor. A time sequence (firstly T, then B) has been disclosed. Granulysin, perforin, granzyme-B and TIA-1 were expressed by Tk cells. The activated Tk cells secrete these mediators as a result of the binding to the tumor target cell, causing its lytic planned death. The cytotoxicity supported by Tk cells appears an important favorable prognostic factor. Therefore, a graduation system for TILs in breast cancer has been here proposed (absent, non-brisk, brisk).

Entities:  

Keywords:  Breast cancer; Granulysin; Histology; Immunohistochemistry; Prognostic factors; Tumor-infiltrating lymphocytes (TILs)

Mesh:

Substances:

Year:  2015        PMID: 26589512     DOI: 10.1007/s12253-015-0024-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  14 in total

1.  Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/ perforin pathway.

Authors:  Jun Zhou; Xiao-Zhen Xu; Yao-Ren Hu; Ai-Rong Hu; Cheng-Liang Zhu; Guo-Sheng Gao
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors.

Authors:  Chris P Miller; Jason D Thorpe; Amanda N Kortum; Catherine M Coy; Wei-Yi Cheng; Tai-Hsien Ou Yang; Dimitris Anastassiou; J David Beatty; Nicole D Urban; C Anthony Blau
Journal:  Cancer Immunol Res       Date:  2014-01-15       Impact factor: 11.151

Review 3.  Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.

Authors:  Bohuslav Melichar; Hana Študentova; Hana Kalábová; Denisa Vitásková; Petra Čermáková; Helena Hornychová; Aleš Ryška
Journal:  Anticancer Res       Date:  2014-03       Impact factor: 2.480

4.  Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.

Authors:  Hajime Kuroda; Jun-ichi Tamaru; Goi Sakamoto; Kiyoshi Ohnisi; Shinji Itoyama
Journal:  Virchows Arch       Date:  2004-11-30       Impact factor: 4.064

5.  Leukocyte composition of human breast cancer.

Authors:  Brian Ruffell; Alfred Au; Hope S Rugo; Laura J Esserman; E Shelley Hwang; Lisa M Coussens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

6.  Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement.

Authors:  K J Busam; C R Antonescu; A A Marghoob; K S Nehal; D L Sachs; J Shia; M Berwick
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

7.  Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.

Authors:  A S Rathore; S Kumar; R Konwar; A N Srivastava; A Makker; M M Goel
Journal:  Indian J Cancer       Date:  2013 Jul-Sep       Impact factor: 1.224

8.  Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy.

Authors:  Sherene Loi
Journal:  Oncoimmunology       Date:  2013-04-30       Impact factor: 8.110

9.  Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.

Authors:  A N Seo; H J Lee; E J Kim; H J Kim; M H Jang; H E Lee; Y J Kim; J H Kim; S Y Park
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

10.  Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.

Authors:  Zonglin Chen; Xianyu Chen; Enxiang Zhou; Ganlong Chen; Ke Qian; Xia Wu; Xiongying Miao; Zhonghua Tang
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more
  6 in total

1.  In Vivo Uptake of Rare Earth Metals by Triple-Negative Breast Cancer Cells.

Authors:  Luca Roncati; Antonietta Morena Gatti; Giuseppe Barbolini; Francesco Piscioli; Teresa Pusiol; Antonio Maiorana
Journal:  Pathol Oncol Res       Date:  2017-02-09       Impact factor: 3.201

2.  Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer.

Authors:  Toni Čeprnja; Ivana Mrklić; Melita Perić Balja; Zlatko Marušić; Valerija Blažićević; Giulio Cesare Spagnoli; Antonio Juretić; Vesna Čapkun; Ana Tečić Vuger; Eduard Vrdoljak; Snježana Tomić
Journal:  J Pers Med       Date:  2022-06-08

Review 3.  Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.

Authors:  Molly A Nelson; Worapol Ngamcherdtrakul; Shiuh-Wen Luoh; Wassana Yantasee
Journal:  Cancer Metastasis Rev       Date:  2021-05-07       Impact factor: 9.237

4.  Paired Box Gene 8 (Pax8) Is also an Immunomarker of B-Cell Lineage Which Can Be Source of Diagnostic Pitfalls.

Authors:  Paolo Gasparri; Luca Roncati
Journal:  Chonnam Med J       Date:  2019-01-25

5.  Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.

Authors:  Lisa König; Fabian D Mairinger; Oliver Hoffmann; Ann-Kathrin Bittner; Kurt W Schmid; Rainer Kimmig; Sabine Kasimir-Bauer; Agnes Bankfalvi
Journal:  BMC Cancer       Date:  2019-02-04       Impact factor: 4.430

6.  Inside a mystery of oncoscience: The cancer-sniffing pets.

Authors:  Luca Roncati
Journal:  Oncoscience       Date:  2019-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.